英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
    WALTHAM, Mass --(BUSINESS WIRE)--Feb 22, 2023-- ImmunoGen, Inc (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
  • ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2009 Financial . . .
    ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three-month period ended December 31, 2008 – the second quarter of the Company’s 2009 fiscal year
  • SEC Filing | ImmunoGen, Inc.
    830 Winter Street, Waltham, MA 02451 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 895-0600Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A 2 below):
  • SGO 2023 - ImmunoGen
    IMMUNOGEN IS NOW PART OF ABBVIE Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline
  • ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2010 Financial . . .
    WALTHAM, Mass , Jan 28, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended December 31, 2009 - the second quarter of the Company's
  • ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2005 Financial . . .
    CAMBRIDGE, Mass --(BUSINESS WIRE)--Aug 11, 2005--ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three- and twelve-month periods ended June 30, 2005
  • SEC Filing | ImmunoGen, Inc.
    Immunogen Inc (Name of Issuer) Common (Title of Class of Securities) 45253H101 (CUSIP Number) March 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) o Rule 13d-1(c) o
  • | ImmunoGen, Inc.
    The Investor Relations website contains information about ImmunoGen, Inc 's business for stockholders, potential investors, and financial analysts
  • ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial . . .
    WALTHAM, Mass --(BUSINESS WIRE)--Aug 6, 2009-- ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the fiscal year and three-month period ended June 30, 2009
  • SEC Filing | ImmunoGen, Inc.
    Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No 333-216438 PROSPECTUS Up to $50,000,000





中文字典-英文字典  2005-2009